GenFleet Therapeutics (GENFLEET-B, 02595) confirmed that shareholders approved every resolution tabled at the 11 May 2026 annual general meeting (AGM), securing both routine business endorsements and refreshed capital-management authorities. The poll was conducted on 370.37 million issued shares—comprising 338.03 million H shares and 32.34 million unlisted shares—with no treasury stock or voting restrictions recorded.

Key Ordinary Resolutions • 2025 Board Report, audited financial statements and annual report each received 99.94% support, with only 0.06% abstentions. • The 2025–2026 directors’ remuneration package mirrored that backing, also at 99.94% approval. • Ernst & Young was re-appointed as external auditor for 2026 with 97.13% support and 2.81% opposition. • Amendments to the working rules for independent non-executive directors and to the related-party transaction management system passed with 99.94% and 99.94% approval, respectively.

Special Resolutions on Capital Management • A new H-share repurchase mandate garnered 99.94% approval. • A general mandate empowering the board to issue shares and dispose of treasury shares was the most contested item, but still cleared the two-thirds threshold with 80.02% for and 19.93% against. • Procedural updates to shareholder and board meeting rules were each backed by 99.94% of votes.

Governance and Compliance All eight directors—three executive, two non-executive and three independent non-executive—attended the AGM either in person or electronically. Computershare Hong Kong Investor Services acted as scrutineer, and the meeting complied with PRC company law, Hong Kong Listing Rules and GenFleet’s articles of association.

With all resolutions carried, GenFleet retains operational continuity, renews its audit engagement and gains flexibility to repurchase or issue shares over the coming year.